

Myeloproliferative

[View the current Myeloproliferative InDepth page on BioPortfolio.com \(PDF\)](#)

(<http://www.bioportfolio.com/indepth/Myeloproliferative.html>) - Regularly Updated.

Recent Publications on Myeloproliferative:



- [Redefining the role of interferon in the treatment of malignant diseases.](#)
*Interferon (IFN) is a cytokine with a long history of use as immunotherapy...*13th November, 2009
Department of Oncology and U.O.C. of Medical Oncology, Ospedale San- Eur J Cancer. 2009 Nov 9. ([DOI Direct Link](#))
- [Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies.](#)
*PURPOSE: Acquired somatic uniparental disomy (UPD) is commonly observed in...*11th November, 2009
Department of Translational Hematology and Oncology Research and- J Clin Oncol. 2009 Nov 9. ([DOI Direct Link](#))
- [Compensated variability in the expression of globin-related genes in erythroblasts generated ex vivo from different donors.](#)
*BACKGROUND: Ex vivo generated erythroblasts are being evaluated for...*7th November, 2009
From Hematology, Oncology and Molecular Medicine and Cell Biology and- Transfusion. 2009 Nov 4. ([DOI Direct Link](#))
- [Myelodysplastic/Myeloproliferative disorder with severe leukocytosis: a case report.](#)
*BACKGROUND: Ex vivo generated erythroblasts are being evaluated for...*6th November, 2009
Department of Internal Medicine, Morehouse School of Medicine, Atlanta,- Am J Clin Oncol. 2009 Jun;32(3):326-7. ([DOI Direct Link](#))
- [Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity.](#)
*PURPOSE: Deregulation of the Janus kinase-signal transducers and...*6th November, 2009
Authors' Affiliations: Departments of Applied Technology, Preclinical- Clin Cancer Res. 2009 Nov 3. ([DOI Direct Link](#))
- [Blood cell activation in myeloproliferative neoplasms.](#)
*PURPOSE: Deregulation of the Janus kinase-signal transducers and...*3rd November, 2009
- Haematologica. 2009 Nov;94(11):1484-8. ([DOI Direct Link](#))
- [Correlation of JAK2 V617F mutant allele quantitation with clinical presentation and type of chronic myeloproliferative neoplasm.](#)
*Activating JAK2 V617F mutation is present in many patients with chronic...*3rd November, 2009
Clinical Pathology Department, William Beaumont Hospital, Royal Oak,- Ann Clin Lab Sci. 2009 Fall;39(4):345-50.
- [Outcome of transplantation for myelofibrosis.](#)

- Myelofibrosis is a myeloproliferative disorder incurable with conventional...* 3rd November, 2009
 Massachusetts General Hospital, Boston, Massachusetts, USA.- Biol Blood Marrow Transplant. 2009
 Oct 29. ([DOI Direct Link](#))
- [JAK2 V617F Mutation Detection: Laboratory Comparison of Two Kits Using RFLP and qPCR.](#)
Aim: The JAK2 V617F mutation has been implicated in a variety of diseases... 3rd November, 2009
 1 Department of Pathology & Laboratory Medicine, American University of- Genet Test Mol
 Biomarkers. 2009 Oct 30. ([DOI Direct Link](#))
 - [Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.](#)
Hairy enhancer of split 1 (Hes1) is a basic helix-loop-helix... 29th October, 2009
 Department of Cell Therapy and Transplantation Medicine, Graduate School- Blood. 2009 Oct 27. ([DOI Direct Link](#))
 - [Treatment of myeloproliferative neoplasms except for chronic leukemia](#)
The discovery of JAK2 mutation has greatly facilitated the approach to... 29th October, 2009
 Intractable Diseases Research Center, Tokyo Medical University.- Nippon Rinsho. 2009
 Oct;67(10):1964-8.
 - [Molecular mechanisms of myeloproliferative diseases and myelodysplastic syndromes](#)
Little was known about the mechanisms for myeloproliferative diseases... 29th October, 2009
 Department of Hematology and Oncology, Research Institute for Radiation- Nippon Rinsho. 2009
 Oct;67(10):1901-5.
 - [Classification of myeloid leukemias](#)
Myeloid leukemia in this series corresponds to the myeloid neoplasms of... 29th October, 2009
 Hematoimmunology, School of Health Science, Faculty of Medicine,- Nippon Rinsho. 2009
 Oct;67(10):1853-62.
 - [Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.](#)
We report the emergence of chronic myelogenous leukemia (CML) in a patient... 28th October, 2009
 Department of Medical Education, Gundersen Lutheran Medical Foundation, La- Clin Lymphoma
 Myeloma. 2009 Oct;9(5):E25-9. ([DOI Direct Link](#))
 - [2-Aminopyrazolo\[1,5-a\]pyrimidines as potent and selective inhibitors of JAK2.](#)
Constitutive activation of the EPO/JAK2 signaling cascade has recently... 28th October, 2009
 Vertex Pharmaceuticals Inc, Cambridge, MA 02139-4242, United States.- Bioorg Med Chem Lett. 2009
 Dec 1;19(23):6529-33. Epub 2009 Oct 24. ([DOI Direct Link](#))

BioNews Results for Myeloproliferative

- [Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics](#)
Nature Reviews Clinical Oncology: Oct 28 2009 4:41PM Matching: myeloproliferative
- [Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics](#)
Nature Chemical Biology: Oct 6 2009 8:42AM Matching: myeloproliferative

Myeloproliferative Clinical Trials:



- [Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder](#)



Myeloproliferative Patents:

- 7579320- [IAP BIR domain binding compounds](#)
- 7592427- [Antibodies to IL-21 receptor](#)
- 7593820- [Crystal structure of human Janus Kinase 2 \(JAK2\) and uses thereof](#)
- 7595038- [Methods of treatment using antibodies to follistatin-3](#)
- 7595154- [Method of detecting a neoplasia associated with an activating platelet derived growth factor receptor alpha \(PDGFRA\) mutation](#)
- 7595337- [Mitotic kinesin inhibitors](#)
- 7597884- [Hyperglycosylated polypeptide variants and methods of use](#)
- 7597886- [Tumor necrosis factor-gamma](#)
- 7597888- [Glycoprotein VI and uses thereof](#)
- 7598057- [Use of cytokine receptors as biomarkers and therapeutic targets in human cancer](#)
- 7598231- [Tricyclic compound, compositions, and methods](#)
- 7592340- [Quinoxalines useful as inhibitors of protein kinases](#)
- 7592010- [Albumin fusion proteins](#)
- 7589118- [IAP BIR domain binding compounds](#)
- 7579355- [Inhibitors of Akt activity](#)
- 7579473- [c-Met modulators and methods of use](#)
- 7582637- [Pyrrolo-pyridine kinase modulators](#)
- 7582668- [Imidazolyl-benzamide anti-cancer agents](#)
- 7585622- [Increasing the proliferative capacity of cells using telomerase reverse transcriptase](#)
- 7585653- [Oncokine fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same](#)
- 7585997- [Compounds and compositions for treating dysproliferative diseases, and methods of use thereof](#)
- 7589068- [Inhibitors of Akt activity](#)
- 7589092- [Prodrugs of heteroaryl compounds](#)
- 7589098- [Methods and compositions utilizing quinazolinones](#)
- 7598245- [Aminotriazole compounds useful as inhibitors of protein kinases](#)
- 7598257- [Heteroaryl substituted pyrrolo\[2,3-b\]pyridines and pyrrolo\[2,3-b\]pyrimidines as janus kinase inhibitors](#)
- 7608392- [Diagnostic assay for measuring a cell mediated immune response](#)
- 7608394- [Methods and compositions for phenotype identification based on nucleic acid methylation](#)
- 7608643- [Compounds for inhibiting KSP kinesin activity](#)
- 7608739- [Mitotic kinesin inhibitors](#)
- 7611879- [27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor](#)
- 7612064- [Sulfopyrroles](#)

- 7612080- [GTPase inhibitors and use thereof for controlling platelet hyperactivity](#)
- 7612104- [Bicyclic aryl-sulfonic acid \[1,3,4\]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use](#)
- 7612178- [Anti-IGF-1R antibodies and uses thereof](#)
- 7615622- [Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII](#)
- 7608274- [Therapeutic processes and useful compositions therefor](#)
- 7608256- [Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response](#)
- 7605266- [Azaindole inhibitors of Aurora kinases](#)
- 7598281- [Arylcycloalkyl-substituted alkanolic acid derivatives useful as peroxisome proliferator-activated receptor \(PPAR\) ligands for the treatment of hyperlipidemia and diabetes](#)
- 7598348- [Adiponectin receptor variant, AdipoR2v2](#)
- 7601839- [Pyrrolo-pyridine kinase modulators](#)
- 7601840- [Carboline derivatives useful in the inhibition of angiogenesis](#)
- 7604944- [Oncokinese fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same](#)
- 7604990- [Methods of regulating differentiation in stem cells](#)
- 7605129- [Splice variant of human placental growth hormone](#)
- 7605142- [Expression of cyclin G1 in tumors](#)
- 7605233- [Tumour necrosis factor binding ligands](#)
- 7605239- [Skeletal-targeted radiation to treat bone-associated pathologies](#)
- 7615628- [Imidazopyridine derivatives](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

